Crohn'sCanada
  Addressing the alarming rise of the bacterium "Mycobacterium avium Paratuberculosis"
 
in the environment and the growing evidence linking this bacterium to Crohn's
disease.

Founders: Diane and Michael Fagen

Contact Info: dianef84@yahoo.com

Home

Our Mission and our Goals

History of Crohn's Disease, Johne's disease, Mycobacterium avium Paratubercuosis

Recent Article Updates

Links to Articles
Page 2....3....4.....5

Perception of Risk

The Precautionary Principle

What is a Reportable Disease

Health of Animals Act, SC 1990, c 21

List of Reportable Diseases and REGULATIONS PRESCRIBING CERTAIN DISEASES AS REPORTABLE DISEASES

NRC National Science Library

Public Health Agency of Canada

Never In My Milk

Picure Gallery

Links

Messageboard

ree Republic/News Activism/Topics - Post Article

Research

La Presse,  April 8, 2001,  Never in My Milk? by Marie France Coutu

The Canadian Media


Canadian Medical and Government

Canadian Veterinary

Canadian Raw Milk Advocacy Group

 

Let's Talk



 

Taking Action

Link To Us

Does Mycobacterium Paratuberculosis cause Crohn's disease by Alan Kennedy  

(PARA) PARATUBERCULOSIS AWARENESS & RESEARCH ASS.,INC



Shafran's Gasterology Center

The Johne's Information Center

History of Early Research on Crohn's disease

Dr. B. Crohn

Got Milk? by Michael Greger, MD Updated January 2001

THE CROHN'S CONNECTION  by Lisa Chamberlain

Dire Warnings About Johne’s
Disease A wake-up call for the dairy industry?

Micobacteria and Crohn's Disease

Dr. Chiodini's Tables

American and European Links

University of Wisconsin School of Veterinary Medicine

Health Canada

Action Medical Research

 

University of Guelph

NACC

 

 

 

LANDMARK CROHN'S DISEASE STUDY by Warwick Selby, June 2007, Pavli P, Crotty B, Florin T, Radford-Smith G, Gibson P, Mitchell B, Connell W, Read R, Merrett M, Ee H, Hetzel D

Antimycobacterial Therapy in Crohn’s Disease: Game Over?/Two-year combination antibiotic therapy with clarithromycin, rifabutin and clofazimine for Crohn’s disease” by Selby W, Pavli P, Crotty B, Florin T, Radford-Smith G, Gibson P, Mitchell B, Connell W, Read R, Merrett M, Ee H, Hetzel D,

 

Flawed Australian CD Study Does Not End MAP Controversy Judith E. Lipton, David P. Barash November 2007

Although the paper by Selby et al1 appears legitimate in its empirical reporting, its conclusions go far beyond its data. No attempt was made to culture or do polymerase chain reaction testing for MAP, either before or after treatment, so no conclusion can be drawn about the effect of their protocol on putative Mycobacterium avium paratuberculosis (MAP) infection. The MAP hypothesis of Crohn’s disease is not tested by this study, nor resolved in anything except the author’s assertions

 

Australian Crohn’s Antibiotic Study Opens New Horizons/Laura Gitlina, James Bieseckerb November 2007

The recently reported trial by Selby et al, “Two year combination antibiotic therapy with Clarithromycin, Rifabutin and Clofazimine for Crohn’s Disease”1 and the accompanying editorial refer to the controversial topic of Crohn’s disease causation by an infectious agent. In this letter, we address 3 important aspects that may have given careful readers concern

 

The Australian Antibiotic Trial in Crohn’s Disease: Alternative Conclusions From the Same Study J. Todd Kuenstner November 2007

I wish to comment on the recent article by Warwick Selby and others entitled, “Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazamine for Crohn’s disease

 

Importance of the Australian Crohn’s Disease Antibiotic Study William Chamberlin November 2007

The article by Warwick Selby, “Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn’s disease”1 and the accompanying commentary2 are well written and worth reading carefully. They contain important data and commentary. Unfortunately, despite data supporting the positive impact of properly chosen antibiotics in treating Crohn’s disease (CD) patients, the authors emphasize the negative. The authors report the data accurately, but their interpretations need to be challenged.

 

GIACONDA LTD.

Myoconda® – A Combination Antibiotic Therapy for the Treatment of Crohn’s Disease a chronic inflammatory disease of the gastrointestinal tract. The disease most commonly affects the lower small intestine and the large intestine. Symptoms of Crohn’s Disease include abdominal pain, diarrhoea, fever and weight loss. In severe cases, the intestine can become blocked or obstructed, requiring surgery. Young patients with Crohn’s Disease may also suffer growth retardation. Patients suffering Crohn’s Disease are conventionally treated with drugs aimed at reducing inflammation and other associated symptoms. The cause of Crohn’s Disease is unknown, thus the standard treatments aim to treat symptoms rather than the cause of the disease. The bacterium Mycobacterium avium paratuberculosis (MAP) is the lead candidate as an infectious cause of Crohn’s Disease. By targeting the MAP infection, Myoconda® is designed to address the possible source of the disease, rather than attempting to merely alleviate its symptoms.

Myoconda®, the Company’s therapy for the treatment of Crohn’s Disease is a combination of three registered antibiotics - rifabutin, clarithromycin and clofazimine. These three drugs are widely marketed world-wide for the treatment of mycobacterial and other infections. Myoconda® presents these three compounds in a specific patented combination. Myoconda® is based on the proposition that Crohn’s Disease is caused by infection. Prof. Borody has long been at the forefront of this approach, which is gaining increasing acceptance among gastrointestinal specialists worldwide. Prof. Borody has published significant data demonstrating that patients treated with Myoconda®’s antibiotic combination experience long-term remission of clinical symptoms and inflammation, some for up to nine years.

Gastroenterology

November 2007:Microbial Mannan Inhibits Bacterial Killing by Macrophages: A Possible Pathogenic Mechanism for Crohn’s Disease Chiedzo M. Mpofu?, Barry J. Campbell?, Sreedhar Subramanian?, Stuart Marshall–Clarke‡, C. Anthony Hart§, Andy Cross?, Carol L. Roberts?, Adrian McGoldrick¶, Steven W. Edwards?1, Jonathan M. Rhodes?1

 

University of Liverpool

Scientists find how bacteria in cows milk may cause Crohn's disease Liverpool, UK - 10 December 2007:

Scientists at the University of Liverpool have found how a bacterium, known to cause illness in cattle, may cause Crohn's disease in humans. Crohn's is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to pain, bleeding and diarrhoea. The team found that a bacterium called Mycobacterium paratuberculosis releases a molecule that prevents a type of white blood cell from killing E.coli bacteria found in the body. E.coli is known to be present within Crohn’s disease tissue in increased numbers.

 

High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease Roman Kotlowski1, Charles N Bernstein3, Shadi Sepehri2, Denis O Krause3

Centre eyes data on bowel disease Sat Jul 28 2007 By Dr. Charles Bernstein

The role of Escherichia coli in inflammatory bowel disease Jonathan M Rhodes

E. coli Bacteria Linked To Crohn's Disease Main Category: GastroIntestinal / Gastroenterology News Article Date: 10 Aug 2007 - 15:00 PDT